Search results for "Lipide"

showing 10 items of 532 documents

IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.

2009

ABSTRACT: The usefulness of a dissolution/permeation (D/P) system to predict the in vivo performance of solid dosage forms containing the poorly soluble drug, fenofibrate, was studied. Biorelevant dissolution media simulating the fasted and fed state conditions of the human gastrointestinal tract were used in order to simulate the effect of food on the absorption of fenofibrate. Moreover, the results obtained from the D/P system were correlated with pharmacokinetic parameters obtained following in vivo studies in rats. The in vitro parameter (amount permeated in the D/P system) reflected well the in vivo performance in rats in terms of AUC and C max of fenofibric acid. This study thus demon…

MaleChemistry PharmaceuticalPharmaceutical ScienceAdministration OralAbsorption (skin)PharmacologyDosage formPermeabilityAbsorptionIVIVCPharmacokineticsFenofibrateIn vivoOral administrationmedicineAnimalsHumansRats WistarHypolipidemic AgentsFenofibrateChemistryPermeationRatsSolubilityCaco-2 Cellsmedicine.drugTabletsJournal of pharmaceutical sciences
researchProduct

Differential regulation by a peroxisome proliferator of the different multifunctional proteins in guinea pig: cDNA cloning of the guinea pig D-specif…

1998

After our previous report on the cloning of two cDNA species in guinea pig, both encoding the same hepatic 79 kDa multifunctional protein 1 (MFP-1) [Caira, Cherkaoui-Malki, Hoefler and Latruffe (1996) FEBS Lett. 378, 57-60], here we report the cloning of a cDNA encoding a second multifunctional peroxisomal protein (MFP-2) in guinea-pig liver. This 2356 nt cDNA encodes a protein of 735 residues (79.7 kDa) whose sequence shows 83% identity with rat MFP-2 [Dieuaide-Noubhani, Novikov, Baumgart, Vanhooren, Fransen, Goethals, Vandekerckhove, Van Veldhoven and Mannaerts (1996) Eur. J. Biochem. 240, 660-666]. In parallel, we studied the effect of ciprofibrate, a hypolipaemic agent also known as per…

MaleDNA ComplementaryTranscription GeneticGuinea PigsMolecular Sequence DataBiologyMicrobodiesBiochemistryEstradiol DehydrogenasesRats Sprague-DawleyGuinea pigClofibric AcidComplementary DNAGene expressionmedicineAnimalsAmino Acid SequenceRNA MessengerNorthern blotCloning MolecularEnoyl-CoA HydrataseMolecular BiologyHypolipidemic AgentsMessenger RNABase SequenceThiolaseFibric AcidsCell BiologyPeroxisomeMolecular biologyRatsGene Expression RegulationLiverBiochemistryCiprofibrateOxidoreductasesResearch Articlemedicine.drugBiochemical Journal
researchProduct

Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia

2018

Although familial hypercholesterolemia (FH) can be effectively managed using cholesterol-lowering medication, patients often fall short of complete treatment adherence. Identifying the psychological factors associated with self-regulation of FH medication is important to inform interventions to maximize adherence. The aim of the present study was to test an integrated psychological model in predicting FH patients' intentions to take medication.FH patients attending clinics in seven countries were invited to participate in a cross-sectional survey study. Consenting patients (N = 551) completed self-report measures of generalized beliefs about medication overuse and harms, beliefs in treatmen…

MaleDisease statusHealth Knowledge Attitudes PracticeTreatment adherencePsychological interventionFamilial hypercholesterolemiaIntention030204 cardiovascular system & hematology0302 clinical medicineuskomuksetMedicinehyperlipidemia030212 general & internal medicineta515common sense modelAnticholesteremic AgentsTheory of planned behaviorSurvey researchta3141Middle AgedTreatment OutcomeSENSO COMUMFemaletheory of planned behaviorCardiology and Cardiovascular MedicinemedicinesAdultmedicine.medical_specialtyDown-RegulationModels PsychologicalRisk AssessmentMedication AdherenceHyperlipoproteinemia Type II03 medical and health sciencesHumansIn patientterve järkiPsychiatryAgedillness perceptionsbusiness.industrysairauskäsityksetCholesterol LDLmedicine.diseaseTaking medicationSelf CarelääkkeetCross-Sectional StudiesbeliefsbusinessBiomarkers
researchProduct

Patients with coronary artery disease and diabetes need improved management : a report from the EUROASPIRE IV survey: a registry from the EuroObserva…

2015

Background: In order to influence every day clinical practice professional organisations issue management guidelines. Cross-sectional surveys are used to evaluate the implementation of such guidelines. The present survey investigated screening for glucose perturbations in people with coronary artery disease and compared patients with known and newly detected type 2 diabetes with those without diabetes in terms of their life-style and pharmacological risk factor management in relation to contemporary European guidelines. Methods: A total of 6187 patients (18-80 years) with coronary artery disease and known glycaemic status based on a self reported history of diabetes (previously known diabet…

MaleEUROASPIRE InvestigatorsCardiac & Cardiovascular SystemsCross-sectional studyEndocrinology Diabetes and MetabolismAngiotensin-Converting Enzyme InhibitorsBlood PressureCoronary Artery DiseaseType 2 diabetesGUIDELINESCoronary artery diseaseMELLITUSRisk FactorsGlycaemic controlMedicine and Health SciencesSecondary PreventionCoronary artery disease ; Type 2 diabetes ; Secondary prevention ; Management ; Guideline adherence ; Blood lipids ; Blood pressure ; Glycaemic controlCardiac and Cardiovascular SystemsRegistriesMyocardial infarctionGLUCOSE CONTROLOriginal InvestigationBLOOD-GLUCOSEType 2 diabetesMiddle AgedManagementEuropeglycaemic controlHypertensionPractice Guidelines as TopicHEARTPlatelet aggregation inhibitorFemaletype 2 diabetesGuideline AdherenceCardiology and Cardiovascular MedicineLife Sciences & Biomedicinemanagementmedicine.medical_specialtyCardiotonic AgentsAdrenergic beta-Antagonists/Endocrinology and Diabetes1102 Cardiovascular Medicine And HaematologyEndocrinology & MetabolismAngiotensin Receptor AntagonistsSDG 3 - Good Health and Well-beingInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agentsddc:610Risk factorAntihypertensive AgentsAgedDyslipidemiasScience & Technologyblood lipidsbusiness.industryMORTALITYCholesterol LDLmedicine.diseaseCross-Sectional StudiesBlood pressureCardiovascular System & HematologyMYOCARDIAL-INFARCTIONDiabetes Mellitus Type 2Cardiovascular System & CardiologyBlood lipidsCARDIOVASCULAR-DISEASESRISK-FACTORSHydroxymethylglutaryl-CoA Reductase InhibitorsFOLLOW-UPbusinessPlatelet Aggregation Inhibitors
researchProduct

Different impacts of cardiovascular risk factors on oxidative stress.

2011

The objective of the study was to evaluate oxidative stress (OS) status in subjects with different cardiovascular risk factors. With this in mind, we have studied three models of high cardiovascular risk: hypertension (HT) with and without metabolic syndrome, familial hypercholesterolemia (FH) and familial combined hyperlipidemia (FCH) with and without insulin resistance. Oxidative stress markers (oxidized/reduced glutathione ratio, 8-oxo-deoxyguanosine and malondialdehide) together with the activity of antioxidant enzyme triad (superoxide dismutase, catalase, glutathione peroxidase) and activation of both pro-oxidant enzyme (NAPDH oxidase components) and AGTR1 genes, as well as antioxidant…

MaleGPX1Antioxidantmedicine.medical_treatmentGlutathione reductaseHyperlipidemia Familial Combinedmedicine.disease_causelcsh:Chemistrychemistry.chemical_compoundRisk FactorsMalondialdehydeoxidative stressglutathione peroxidaselcsh:QH301-705.5Spectroscopychemistry.chemical_classificationbiologyfamilial hypercholesterolemiaChemistryGlutathione peroxidaseGeneral MedicineMiddle AgedCatalaseGlutathioneComputer Science ApplicationsGlutathione Reductase8-Hydroxy-2'-DeoxyguanosineCardiovascular DiseasesFemaleThioredoxinAdultmedicine.medical_specialtyhypertensionmRNACatalysisGlutathione SynthaseArticleInorganic ChemistrySuperoxide dismutaseHyperlipoproteinemia Type IIInternal medicinemedicineHumansPhysical and Theoretical ChemistryMolecular BiologySuperoxide DismutaseGene Expression ProfilingOrganic ChemistryDeoxyguanosineNADPH OxidasesGlutathionesuperoxide dismutasesPhosphoproteinscombined familial dyslipidemiaEndocrinologylcsh:Biology (General)lcsh:QD1-999biology.proteinOxidative stressBiomarkersInternational journal of molecular sciences
researchProduct

Is the Physician’s Behavior in Dyslipidemia Diagnosis in Accordance with Guidelines? Cross-Sectional Escarval Study

2013

Background: Clinical inertia has been defined as mistakes by the physician in starting or intensifying treatment when indicated. Inertia, therefore, can affect other stages in the healthcare process, like diagnosis. The diagnosis of dyslipidemia requires $ 2 high lipid values, but inappropriate behavior in the diagnosis of dyslipidemia has only previously been analyzed using just total cholesterol (TC). Objectives: To determine clinical inertia in the dyslipidemia diagnosis using both TC and high-density lipoprotein cholesterol (HDL-c) and its associated factors. Design: Cross-sectional. Setting: All health center visits in the second half of 2010 in the Valencian Community (Spain). Patient…

MaleHealth ScreeningNon-Clinical MedicineCross-sectional studyHealth Care ProvidersCardiovascularchemistry.chemical_compoundRisk FactorsOdds RatioPractice Patterns Physicians'Young adultHealth Systems StrengtheningMultidisciplinaryCommunicationQRAtrial fibrillationMiddle AgedCholesterolMedicineFemalelipids (amino acids peptides and proteins)Guideline AdherencePublic HealthResearch ArticleAdultmedicine.medical_specialtyClinical Research DesignScienceCardiologyYoung AdultDiagnostic MedicinePhysiciansInternal medicineDiabetes mellitusmedicineHumansHealth Care QualityAgedDyslipidemiasHealth Care Policybusiness.industryCholesterolCholesterol HDLOdds ratiomedicine.diseaseMiddle ageCross-Sectional StudieschemistrySpainPreventive MedicinebusinessDyslipidemia
researchProduct

Association of Osteoarthritis with Increased Risk of Cardiovascular Diseases in the Elderly: Findings from the Progetto Veneto Anziano Study Cohort

2015

Objective The possible relevance of osteoarthritis (OA) as a cardiovascular disease (CVD) risk factor is still debated. The aim of this study was to investigate the association between OA and the onset of CVD in older individuals. Methods Among a sample of 3,099 elderly subjects, 2,158 were identified as having no CVD at baseline and were followed up for a mean ± SD 4.4 ± 1.2 years. OA was defined using a standardized algorithm that investigated disease history, medical documentation (including radiographic reports), symptoms, and physical examination of the joints. Incident CVD was defined as the onset of coronary artery disease, heart failure, stroke/transient ischemic attack, peripheral …

MaleIMPACTImmunologyUNITED-STATESPROGRESSIONCoronary Artery DiseaseKNEE OSTEOARTHRITISNOCohort StudiesPeripheral Arterial DiseaseRheumatologyImmunology; Immunology and Allergy; RheumatologyRisk FactorsOsteoarthritisEPIDEMIOLOGYHumansImmunology and AllergyObesityAgedDyslipidemiasProportional Hazards ModelsAged 80 and overHeart FailureDISABILITYMORTALITYIncidencePREVALENCEHospitalizationLipoproteins LDLStrokeATHEROSCLEROSISItalyCardiovascular DiseasesIschemic Attack TransientHypertensionFemaleARTHRITISFollow-Up Studies
researchProduct

Expression of liver peroxisomal proteins as compared to other organelle marker enzymes in rats treated with hypolipidemic agents.

1990

Abstract Peroxisome proliferation induced by 2 hypolipidemic agents (clofibrate and ciprofibrate) was studied in rats by complementary approaches, ie cell fractionation, electron microscopy, marker enzyme activities, immunoblotting and nucleic acid hybridization techniques. Administration of clofibrates for 2 and 52 weeks in doses of 500 ppm and 50 ppm respectively, or ciprofibrate for 2,28 and 52 weeks in doses of 250, 25 and 25 ppm respectively, did not alter the behavior of the peroxisomes after induction as shown by ultracentrifugation profiles. The peroxisome mass was increased as shown by the purification procedure. Specific enzymes (catalase and mostly cyanide insensitive palmitoyl C…

MaleImmunoblottingMolecular Sequence DataPeroxisome ProliferationMitochondrionCell FractionationMicrobodiesClofibric AcidOrganellemedicineAnimalsClofibrateRNA MessengerHypolipidemic AgentsOrganellesClofibratebiologyBase SequenceEndoplasmic reticulumFibric AcidsRats Inbred StrainsCell BiologyGeneral MedicinePeroxisomeMolecular biologyRats Inbred F344RatsBiochemistryLiverCatalasebiology.proteinCiprofibrateDNA Probesmedicine.drugBiology of the cell
researchProduct

Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial

2012

Background The effects of different hypolipidemic treatment strategies on emerging atherosclerosis risk factors remain unknown. Materials and methods This is a prespecified analysis of a prospective, randomized, open-label, blinded end point (PROBE) study (ClinicalTrials.gov identifier: NCT01010516). Patients (n = 100) with mixed dyslipidaemia on a standard statin dose who had not achieved lipid targets were randomized to switch to the highest dose of rosuvastatin (40 mg/day) or to add-on-statin extended release nicotinic acid (ER-NA)/laropiprant (LRPT) or to add-on-statin micronized fenofibrate for a total of 3 months. Results Following 3 months of treatment, low-density lipoprotein (LDL) …

MaleIndolesTime FactorsClinical BiochemistryPilot ProjectsPharmacologyBiochemistryGastroenterologychemistry.chemical_compoundFenofibrateRisk FactorsProspective StudiesRosuvastatin CalciumHypolipidemic AgentsSulfonamidesFenofibratebiologyGeneral MedicineMiddle AgedRosuvastatin CalciumC-Reactive ProteinCardiovascular DiseasesDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Laropiprantmedicine.drugAdultmedicine.medical_specialtyStatinmedicine.drug_classNiacinInternal medicinemedicineHumansRosuvastatinAgedApolipoproteins BDyslipidemiasbusiness.industryCholesterolC-reactive proteinnutritional and metabolic diseasesCholesterol LDLAtherosclerosismedicine.diseaseFluorobenzenesPyrimidineschemistry1-Alkyl-2-acetylglycerophosphocholine Esterasebiology.proteinHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemiaEuropean Journal of Clinical Investigation
researchProduct

Prevalence of corneal arcus and associated factors in a German population-Results from the Gutenberg Health Study.

2021

Purpose We aimed to determine the prevalence of corneal arcus and to identify associated factors in the general population of Germany. Methods The Gutenberg Health Study (GHS) is a population-based cohort study in Germany, which includes an ophthalmological assessment. Refraction, distance-corrected visual acuity, non-contact tonometry and anterior segment imaging were performed for the five-year follow-up examination. Anterior segment photographs were graded for the presence of corneal arcus. Prevalence estimates were computed, and multivariable logistic regression analysis was applied to determine associated factors for corneal arcus including sex, age, spherical equivalent, central corn…

MaleIntraocular pressureVisual acuitygenetic structuresVisual AcuityBlood PressureCardiovascular MedicineBiochemistryVascular MedicineGeographical locationsCorneaMedical ConditionsEndocrinologyCorneaGermanyMedicine and Health SciencesPrevalenceProspective StudiesDioptreeducation.field_of_studyMultidisciplinaryQRMiddle AgedLipidsEuropemedicine.anatomical_structureCholesterolCardiovascular DiseasesMedicineFemalemedicine.symptomAnatomyCohort studyResearch Articlemedicine.medical_specialtyEndocrine DisordersOcular AnatomySciencePopulationCardiologyArcus SenilisOcular SystemOphthalmologymedicineDiabetes MellitusHumansEuropean UnioneducationIntraocular Pressurebusiness.industryBiology and Life SciencesCardiovascular Disease Riskmedicine.diseaseeye diseasesBlood pressureCross-Sectional StudiesMetabolic DisordersEyessense organsPeople and placesbusinessHeadDyslipidemiaPLoS ONE
researchProduct